ImetelChat

SAT
You posted- "It does make you wonder though how urgent hematologists will feel the need is for Imetelstat if they can simply follow Moffet's BAT and see such impressive mOS. Keeping in mind that Rytelo is an expensive drug it may come to pass that Rytelo is used as a salvage treatment for many ...

Geron will also have additional presentations at the EHA 2026 Congress and the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, including abstracts related to its ongoing myelofibrosis clinical programs. This includes an updated overall survival analysis in patients with ...

That is how I would describe the quarterly report today. The numbers indicate a nice positive progression. Nothing real exciting, just good. Maybe put some sanity into the PPS now as company seems more stable and more on a positive track. I heard something about readout second half of 2026. Can ...

Biopearl
Interesting and quite exhaustive! I for one would be interested in your take. I hope I am capable of drawing my own conclusions, but I know I am not capable of doing all the questions you asked.

Is this too good to be true? Sounds great. Also scary for insider information. The dream I think is that all people could access the ongoing data and we investors could make more informed decisions and so could patients and their families.

yes, imetelstat has received orphan drug designation from the FDA for certain hematologic diseases in the past.

What this typically means:

It has been designated as an Orphan Drug for conditions like myelofibrosis and essential thrombocythemia (and possibly others) at various times.

Two very impressive additions to the board today. One appears to be very experienced with companies that get bought out.

I read elsewhere that they had missed some important goal. Overall, appears to me a weak company with weak results.

I hope the new boss does better than the previous boss sitting round the campfire. I like the flurry of activity set for after the earnings report.

FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to purchase an aggregate of 742,500 shares of common stock to one newly hired employee as ...

That is very nice research finding!

Feeble memory, but does Geron have a manufacturing arrangement with a company in India? If so, does the tariff truce today with India have something to do with the stock jump?

Is this the Faye Feller mystery solved?............
Her LinkedIn profile has also been updated to reflect her departure.

While she was still posting about Geron's clinical trial data from ASH 2024 as recently as December 16, 2024, her profile now lists her tenure at Geron as having ended in 2025 ...

o
$220M-$240M in expected 2026RYTELO net product revenue,

That language is a bit confusing. The use of net here seems wrong. I think he means gross income.

Is this HUGE?

From AI
the nccn updated its clinical practice guidelines in oncology for myelodysplastic syndromes (mds) to include rytelo in two major ways, both of which materially improve its commercial and clinical positioning. all facts below are sourced from the nccn‑related announcements. rytelo is now a ...

The NCCN updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS) to include RYTELO in two major ways, both of which materially improve its commercial and clinical positioning.

All facts below are sourced from the NCCN‑related announcements.

Rytelo is now a Category ...

This is huge! Hopefully it is a move of strength-seems so. Many of us have wondered if there wasn't a lot of fat and possible cronyism going on with all the hires.

Inspire Medical Systems (NASDAQ: INSP) faces heightened execution risk following a sharp 2025 earnings guidance cut tied to weak Inspire V adoption and operational missteps, including staffing and billing issues; the resulting class-action lawsuits underscore investor concerns about management ...

Well said, Biopearl! I never got any response either when I asked about Dr. Feller.